

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

LASERSIGHT INC /DE
Form 10-Q
November 14, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2002.

or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Transition period from _____ to _____

Commission File Number: 0-19671

LASERSIGHT INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware

65-0273162

(State of Incorporation)

(IRS Employer Identification No.)

3300 University Blvd., Suite 140, Winter Park, Florida 32792

(Address of principal executive offices) (Zip Code)

(407) 678-9900

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No
----- -----

The Number of shares of the registrant's Common Stock outstanding as of November 13, 2002 is 27,841,941.

LASERSIGHT INCORPORATED AND SUBSIDIARIES

Except for the historical information contained herein, the discussion in this report contains forward-looking statements (within the meaning of Section 21E of the Exchange Act) that involve risks and uncertainties. LaserSight's actual results could differ materially from those discussed here. Factors that could

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Factors and Uncertainties" in this report and in LaserSight's Annual Report on Form 10-K for the year ended December 31, 2001. LaserSight undertakes no obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect any future events or developments.

INDEX

PART I. FINANCIAL INFORMATION

- Item 1. Condensed Consolidated Financial Statements
 - Condensed Consolidated Balance Sheets as of September 30, 2002 and December 31, 2001
 - Condensed Consolidated Statements of Operations for the Three Month Periods and Nine Month Periods Ended September 30, 2002 and 2001
 - Condensed Consolidated Statements of Cash Flows for the Nine Month Periods Ended September 30, 2002 and 2001
 - Notes to Condensed Consolidated Financial Statements
 - Independent Auditors' Review Report
- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
- Item 3. Management's Quantitative and Qualitative Disclosures about Market Risk
- Item 4. Controls and Procedures

PART II. OTHER INFORMATION

- Item 1. Legal Proceedings
- Item 2. Changes in Securities
- Item 3. Defaults Upon Senior Securities
- Item 4. Submission of Matters to a Vote of Security Holders
- Item 5. Other Information
- Item 6. Exhibits and Reports on Form 8-K

2

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

LASERSIGHT INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

ASSETS	September 30, 2002

Current assets:	(Unaudited)
Cash and cash equivalents	\$ 403,874
Accounts receivable - trade, net	5,185,210
Notes receivable - current portion, net	2,209,096
Inventories	9,807,685
Deferred tax assets	40,214
Other current assets	179,764

Total Current Assets	17,825,843
Notes receivable, less current portion, net	1,362,189
Property and equipment, net	632,797
Patents, net	4,240,911
Other assets, net	1,128,781

	\$ 25,190,521
	=====
LIABILITIES AND STOCKHOLDERS' EQUITY	
Current liabilities:	
Note payable, net of unamortized discount of \$27,567 at September 30, 2002	\$ 2,352,433
Accounts payable	3,562,139
Accrued expenses	5,975,420
Accrued commissions	1,555,901
Deferred revenue	1,813,189

Total Current Liabilities	15,259,082
Accrued expenses, less current portion	218,756
Deferred royalty revenue, less current portion	5,976,751
Deferred income taxes	40,214
Note payable, net of unamortized discount of \$73,530 at December 31, 2001	--
Commitments and contingencies	
Stockholders' equity:	
Convertible preferred stock, authorized 10,000,000 shares; par value \$.001 per share:	
Series F - zero and 1,276,596 issued and outstanding at September 30, 2002 and December 31, 2001, respectively	--
Common stock - par value \$.001 per share; authorized 100,000,000 shares; 27,987,141 and 26,596,062 shares issued at September 30, 2002 and December 31, 2001, respectively	27,987
Additional paid-in capital	101,981,093
Stock subscription receivable	(47,952)
Accumulated deficit	(97,722,763)
Less treasury stock, at cost; 145,200 common shares at September 30, 2002 and December 31, 2001	(542,647)

	3,695,718

	\$ 25,190,521
	=====

See accompanying notes to the condensed consolidated financial statements.

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

3

LASERSIGHT INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended September 30,		Nine Months September
	2002	2001	2002
Revenues:			
Products	\$ 2,526,171	2,054,407	5,752,087
Royalties	224,096	72,000	867,009
	-----	-----	-----
	2,750,267	2,126,407	6,619,096
Cost of revenue:			
Product cost	1,417,219	1,382,714	3,851,799
	-----	-----	-----
Gross profit	1,333,048	743,693	2,767,297
Research, development and regulatory expenses	203,288	712,693	1,138,500
Other general and administrative expenses	2,489,047	5,268,858	10,622,854
Selling related expenses	764,668	1,045,456	2,226,855
Amortization of intangibles	115,059	115,059	345,177
	-----	-----	-----
	3,368,774	6,429,373	13,194,886
Loss from operations	(2,239,014)	(6,398,373)	(11,566,089)
Other income and expenses			
Interest and dividend income	69,077	124,416	215,018
Interest expense	(141,653)	(149,212)	(439,636)
Gain on sale of patent	--	--	--
Litigation settlement	(140,000)	--	(140,000)
	-----	-----	-----
Loss from continuing operations before income tax expense	(2,451,590)	(6,423,169)	(11,930,707)
Income tax expense	--	--	--
	-----	-----	-----
Loss from continuing operations	(2,451,590)	(6,423,169)	(11,930,707)
Discontinued operations:			
Loss from the operation of discontinued health care services business	--	(93,019)	--
	-----	-----	-----
Net loss	\$ (2,451,590)	(6,516,188)	(11,930,707)
	=====	=====	=====
Loss per common share			
Basic and diluted:	\$ (0.09)	(0.25)	(0.44)

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

	=====	=====	=====
Weighted average number of shares outstanding			
Basic and diluted:	27,842,000	26,392,000	27,116,000
	=====	=====	=====

See accompanying notes to the condensed consolidated financial statements.

4

LASERSIGHT INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001
(Unaudited)

	2002	2001
	-----	-----
Cash flow from operating activities		
Net loss	\$(11,930,707)	(17,668,814)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	1,281,147	1,704,643
Gain on sale of patent	--	(3,950,836)
Common stock issued for services	42,500	60,469
Options issued in relation to consulting agreement	12,377	33,715
Changes in assets and liabilities:		
Accounts and notes receivable	4,693,439	2,129,970
Inventories	2,197,423	(247,184)
Accounts payable	(284,767)	(559,766)
Accrued expenses	(214,652)	(1,220,466)
Deferred revenue	1,730,348	4,048,904
Other	639,599	(99,827)
	-----	-----
Net cash used in operating activities	(1,833,293)	(15,769,192)
Cash flows from investing activities		
Purchases of property and equipment, net	(4,437)	(381,263)
Proceeds from sale of patent, net	--	6,365,000
	-----	-----
Net cash provided by (used in) investing activities	(4,437)	5,983,737
Cash flows from financing activities		
Payments on debt financing	(620,000)	--
Proceeds from stock subscription receivable	98,402	--
Proceeds from preferred stock financing, net	--	2,925,000
Proceeds from ESPP	1,140	59,891
Proceeds from debt financing, net	--	2,776,798
	-----	-----
Net cash provided by (used in) financing activities	(520,458)	5,761,689
	-----	-----
Decrease in cash and cash equivalents	(2,358,188)	(4,023,766)
Cash and cash equivalents, beginning of period	2,762,062	8,593,858
	-----	-----
Cash and cash equivalents, end of period	\$ 403,874	4,570,092
	=====	=====

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

See accompanying notes to the condensed consolidated financial statements.

5

LASERSIGHT INCORPORATED AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Nine Month Periods Ended September 30, 2002 and 2001

NOTE 1 BASIS OF PRESENTATION

The accompanying unaudited, condensed consolidated financial statements of LaserSight Incorporated and subsidiaries (LaserSight, or the Company) as of September 30, 2002, and for the three and nine month periods ended September 30, 2002 and 2001 have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. The Company has suffered recurring losses from operations and has a significant accumulated deficit that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described below. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company has incurred significant losses and negative cash flows from operations in each of the years in the three-year period ended December 31, 2001 and in the three and nine month periods ended September 30, 2002 and has an accumulated deficit of \$97,722,763 at September 30, 2002. The substantial portion of these losses is attributable to an inability to sell certain products in the U.S. due to delays in Food and Drug Administration (FDA) approvals for the treatment of various procedures on the Company's excimer laser system in the U.S. (a key approval for the treatment of nearsightedness with or without astigmatism was received in late September 2001) and the continued development efforts to expand clinical approvals of the Company's excimer laser and other products.

The Company has significant liquidity and capital resource issues relative to the timing of our accounts receivable collection and the successful completion of new sales compared to our ongoing payment obligations. In July 2002, the Company announced it had entered a letter of intent with a company based in the People's Republic of China. Definitive agreements relating to the transaction were executed in August 2002 and include their commitment to purchase \$10 million of lasers and other products over a 12-month period ending in August 2003 and an equity investment in LaserSight of \$2.0 million. The Company started shipping products under those agreements in August 2002 and received the equity investment in October 2002. As a result, the Company's short-term liquidity has improved and its operating results are improving. Management of the Company continues undertaking steps as part of a plan to attempt to continue to improve liquidity and operating results with the goal of sustaining Company operations. These steps include seeking (a) to increase sales; and (b) to control overhead costs and operating expenses.

There can be no assurance the Company can successfully accomplish these steps. Accordingly, the Company's ability to continue as a going concern is uncertain and dependent upon continuing to achieve improved

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

operating results and cash flows or obtaining additional equity capital and/or debt financing. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business.

6

The condensed consolidated financial statements have been prepared in accordance with the requirements for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in LaserSight's annual report on Form 10-K for the year ended December 31, 2001. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary for a fair presentation of consolidated financial position and the results of operations and cash flows for the periods presented. There are no other components of comprehensive loss other than the Company's consolidated net loss for the three and nine month periods ended September 30, 2002 and 2001. The results of operations for the three and nine month periods ended September 30, 2002 are not necessarily indicative of the operating results for the full year. The report of KPMG LLP, independent auditors, commenting upon their review accompanies the condensed consolidated financial statements included in Item 1 of Part I.

NOTE 2 PER SHARE INFORMATION

Basic loss per common share is computed using the weighted average number of common shares and contingently issuable shares (to the extent that all necessary contingencies have been satisfied). Diluted loss per common share is computed using the weighted average number of common shares, contingently issuable shares, and common share equivalents outstanding during each period. Common share equivalents include options, warrants to purchase Common Stock, and convertible Preferred Stock and are included in the computation using the treasury stock method if they would have a dilutive effect.

NOTE 3 INVENTORIES

Inventories, which consist primarily of excimer and erbium laser systems and related parts and components, are stated at the lower of cost or market. Cost is determined using the standard cost method, which approximates cost determined on the first-in first-out basis. The components of inventories at September 30, 2002 and December 31, 2001 are summarized as follows:

	September 30, 2002	December 31, 2001
	-----	-----
Raw materials	\$ 6,530,414	7,699,939
Work-in-process	113,318	92,030
Finished goods	2,369,505	3,563,796
Test equipment - clinical trials	794,448	649,343
	-----	-----
	\$ 9,807,685	12,005,108
	=====	=====

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

NOTE 4 SEGMENT INFORMATION

The Company's continuing operations principally include refractive products. Refractive product operations primarily involve the development, manufacture and sale of ophthalmic lasers and related devices for use in vision correction procedures. Patent services involve the revenues and expenses generated from the ownership of certain refractive laser patents. Health care services provided health and vision care consulting services to hospitals, managed care companies, and physicians, and was reflected as a discontinued operation as of December 31, 2001.

Operating profit is total revenue less operating expenses. In determining operating profit for operating segments, the following items have not been considered: general corporate expenses,

7

discontinued operations, non-operating income and expense and income tax expense. Identifiable assets by operating segment are those that are used by or applicable to each operating segment. General corporate assets consist primarily of cash and income tax accounts.

The table below summarizes information about reported segments as of and for the three months ended September 30:

	Operating Revenues -----	Operating Profit (Loss) -----	Assets -----	Depreciati and Amortizati -----
2002				
Operating segments:				
Refractive products	\$ 2,526,171	(2,077,003)	24,374,832	321,5
Patent services	224,096	224,096	--	
General corporate	--	(386,107)	815,689	4
	-----	-----	-----	-----
Consolidated total	\$ 2,750,267	(2,239,014)	25,190,521	322,0
	=====	=====	=====	=====
2001				
Operating segments:				
Refractive products	\$ 2,054,407	(6,186,116)	34,970,792	425,1
Patent services	72,000	72,000	--	
Discontinued operations	--	--	3,290,609	70,5
General corporate	--	(284,257)	4,935,744	2,4
	-----	-----	-----	-----
Consolidated total	\$ 2,126,407	(6,398,373)	43,197,145	498,1
	=====	=====	=====	=====

Amortization of deferred financing costs and discount on note payable of \$63,612 for each of the three months ended September 30, 2002 and 2001 is included as interest expense.

The table below summarizes information about reported segments as of and for the nine months ended September 30:

Operating	Operating	Depreciati and
-----------	-----------	-------------------

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

	Revenues	Profit (Loss)	Assets	Amortizati
	-----	-----	-----	-----
2002				
Operating segments:				
Refractive products	\$ 5,752,087	(11,163,814)	24,374,832	1,087,6
Patent services	867,009	867,009	--	
General corporate	--	(1,269,284)	815,689	2,6
	-----	-----	-----	-----
Consolidated total	\$ 6,619,096	(11,566,089)	25,190,521	1,090,3
	=====	=====	=====	=====
2001				
Operating segments:				
Refractive products	\$ 9,155,980	(20,055,632)	34,970,792	1,347,0
Patent services	320,000	320,000	--	
Discontinued operations	--	--	3,290,609	209,7
General corporate	--	(1,202,045)	4,935,744	7,8
	-----	-----	-----	-----
Consolidated total	\$ 9,475,980	(20,937,677)	43,197,145	1,564,6
	=====	=====	=====	=====

Amortization of deferred financing costs and discount on note payable of \$190,836 and \$139,946 for the nine months ended September 30, 2002 and 2001, respectively, is included as interest expense.

8

NOTE 5 AMENDED LOAN AGREEMENT

On August 15, 2002, Heller Healthcare Finance, Inc. (Heller) provided a waiver of the Company's prior defaults under our loan agreement pending the funding of the equity portion of the China transaction (see note 8). Upon receipt of the equity investment in October 2002, revised covenants became effective that decreased the required minimum level of net worth to \$2.1 million, decreased minimum tangible net worth to negative \$2.8 million and decreased minimum quarterly revenues during the last two quarters of 2002 and the first quarter of 2003. In exchange for the waiver and revised covenants, the Company paid \$150,000 in principal to Heller upon the receipt of the equity investment in October 2002 and agreed to increase other monthly principal payments to \$60,000 in October 2002 and \$40,000 during each of November and December 2002 and January 2003. The remaining principal balance is due on March 12, 2003. The Company is currently unable to borrow under its revolving credit facility.

NOTE 6 PATENT LICENSES

Letter of Intent and License of Patents and Technology

On April 16, 2002, the Company announced that it had entered into a letter of intent and a non-exclusive license with a third party contemplating the sale of patents and technology related to its AstraMax diagnostic workstation product. On May 14, 2002, the Company announced the transaction had been terminated. The third party has alleged that the Company violated the terms of the non-exclusive license. The Company denies any intent to do so. Prior to the termination of the process, the Company received cash payments totaling \$875,000. Of this amount, \$275,000 is included in royalty revenue during the three months ended June 30, 2002. In May 2002, the Company

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

settled the dispute with the third party by granting that third party a license to the Company's U.S. Patent No. RE 37,504 ('504 Scanning Patent). Therefore, the remaining \$600,000 was recorded as deferred revenue in the accompanying condensed consolidated balance sheet and is being amortized over approximately 10 years.

Patent License

On May 24, 2002, the Company entered into a non-exclusive license with a third party related to its scanning patent in exchange for cash consideration of \$2.0 million. This amount was recorded as deferred revenue in the accompanying condensed consolidated balance sheet and is being amortized over approximately 10 years. Of this amount, \$500,000 was paid to Heller to reduce principal outstanding on the Company's term loan.

NOTE 7 STOCKHOLDERS' EQUITY

In April 2002, the Company settled litigation related to its stock subscription receivable and received approximately \$82,000 with a commitment for an additional total of approximately \$64,000 to be paid in four quarterly installments beginning in July 2002. The first two installments were received in July and October 2002, respectively. Upon receipt of the two remaining installments in a timely manner, the Company will release all claims in this matter.

NOTE 8 STRATEGIC TRANSACTION

On August 15, 2002, the Company executed definitive agreements with a company based in the People's Republic of China that specializes in advanced medical treatment services, medical device distribution and medical project investment. The transaction established a strategic relationship that include the commitment to purchase at least \$10.0

9

million worth of Company products during the 12-month period following the signing of the definitive agreements, distribution of Company products in mainland China, Hong Kong, Macao and Taiwan, and a \$2.0 million investment in the Company (see note 9). Under the terms of the agreements, the products purchased are being paid by irrevocable letters of credit, confirmed by a U.S. bank and payable upon presentation of shipping documents. Through September 30, 2002, approximately \$1.0 million worth of products were sold under these agreements.

NOTE 9 SUBSEQUENT EVENT

In October 2002, the investment called for under the agreements with the China-based group (see note 8) was completed. In exchange for its \$2.0 million investment, the Company issued the China-based group 9,280,647 shares of Series H Convertible Preferred Stock that, subject to certain restrictions, could be converted into 18,561,294 shares of the Company's Common Stock and result in the purchaser holding approximately 40% of the Company's Common Stock.

10

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

The Board of Directors
LaserSight Incorporated:

We have reviewed the condensed consolidated balance sheet of LaserSight Incorporated and subsidiaries as of September 30, 2002, and the related condensed consolidated statements of operations for the three and nine-month periods ended September 30, 2002 and 2001 and the condensed consolidated statements of cash flows for the nine-month periods ended September 30, 2002 and 2001. These condensed consolidated financial statements are the responsibility of the Company's management.

We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States of America, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet of LaserSight Incorporated and subsidiaries as of December 31, 2001, and the related consolidated statements of operations, stockholders' equity, and cash flows for the year then ended (not presented herein); and in our report dated March 22, 2002, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2001, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

Our report dated March 22, 2002, on the consolidated financial statements of LaserSight Incorporated and subsidiaries as of and for the year ended December 31, 2001, contains an explanatory paragraph that states that the Company's recurring losses from operations and significant accumulated deficit raise substantial doubt about the entity's ability to continue as a going concern. The consolidated balance sheet as of December 31, 2001, does not include any adjustments that might result from the outcome of that uncertainty.

/s/ KPMG LLP

St. Louis, Missouri
November 9, 2002

11

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

LaserSight is principally engaged in the manufacture and supply of narrow beam scanning excimer laser systems, topography-based diagnostic workstations, keratomes, keratome blades and other related products used to perform procedures that correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism. Since 1994, we have marketed our laser systems commercially in over 30 countries worldwide and currently have an installed base

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

of approximately 400 laser systems, including over 220 of our LaserScan LSX(TM) laser systems. We are currently focused on selling in selected international markets while we await further regulatory approvals of our laser product in the U.S.

We have significant liquidity and capital resource issues relative to the timing of our accounts receivable collection and the successful completion of new sales compared to our ongoing payment obligations and our recurring losses from operations and net capital deficiency raises substantial doubt about our ability to continue as a going concern. We have experienced significant losses and operating cash flow deficits, and we expect that operating cash flow deficits will continue without improvement in our operating results. In August 2002, we executed definitive agreements relating to our China Transaction (see "China Transaction"). As a result, the Company's short-term liquidity has improved and its operations are improving. Further improvements in revenues will be needed to achieve profitability and positive cash flow.

CHINA TRANSACTION

In July 2002, we signed a non-binding letter of intent with a company based in the People's Republic of China that specializes in advanced medical treatment services, medical device distribution and medical project investment. Definitive agreements relating to the China Transaction were executed on August 15, 2002, establishing a strategic relationship that includes the commitment to purchase at least \$10.0 million worth of our products during the 12-month period ending August 15, 2003, distribution of our products in mainland China, Hong Kong, Macao and Taiwan, and a \$2.0 million investment in LaserSight. The investment was completed in October 2002 in the form of Series H convertible preferred stock that, subject to certain restrictions, could be converted into shares of the our common stock and result in the purchaser holding approximately 40% of our common stock. The products purchased will be paid by irrevocable letters of credit, confirmed by a U.S. bank and payable upon presentation of shipping documents. The Company started shipping products under this agreement in August 2002. Through September 30, 2002, approximately \$1.0 million worth of products were sold under these agreements.

RESULTS OF OPERATIONS

The following table sets forth for the periods indicated information derived from our statements of operations for those periods expressed as a percentage of net sales, and the percentage change in such items from the comparable prior year period. Any trends illustrated in the following table are not necessarily indicative of future results.

12

	As a Percentage of Net Revenues				Percent Increase (Decrease) Over Prior Period	
	Three Months		Nine Months		Three Months	Nine Months
	Ended	Ended	Ended	Ended	Ended	Ended
	September 30,	September 30,	September 30,	September 30,	September 30,	September 30,
	2002	2001	2002	2001	2002 vs. 2001	2002 vs. 2001
	-----	-----	-----	-----	-----	-----
Statement of Operations Data:						
Net Revenues:						
Refractive products.....	91.9%	96.6%	86.9%	96.6%	23.0%	

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

Patent service.....	8.1	3.4	13.1	3.4	211.2
	-----	-----	-----	-----	
Net Revenues.....	100.0	100.0	100.0	100.0	29.3
Cost of Revenue.....	51.5	65.0	58.2	51.3	2.5
	-----	-----	-----	-----	
Gross Profit (1).....	48.5	35.0	41.8	48.7	79.2
Research, development and regulatory expenses (2).....	7.4	33.5	17.2	27.3	(71.5)
Other general and administrative expenses.....	90.5	247.8	160.5	199.2	(52.8)
Selling-related expenses (3).....	27.8	49.2	33.6	39.1	(26.9)
Amortization of intangibles.....	4.2	5.4	5.2	4.1	0.0
	-----	-----	-----	-----	
Loss from continuing operations....	(81.4)	(300.9)	(174.7)	(221.0)	(65.0)

-
- (1) As a percentage of net revenues, the gross profit for refractive products only for the three months ended September 30, 2002 and 2001, and the nine months ended September 30, 2002 and 2001, was 44%, 33%, 33% and 47%, respectively.
- (2) As a percentage of refractive product net sales, research, development and regulatory expenses for each of the three months ended September 30, 2002 and 2001, and the nine months ended September 30, 2002 and 2001, were 8%, 35%, 20% and 28%, respectively.
- (3) As a percentage of refractive product net sales, selling-related expenses for the three months ended September 30, 2002 and 2001, and the nine months ended September 30, 2002 and 2001, were 30%, 51%, 39% and 40%, respectively.

THREE MONTHS ENDED SEPTEMBER 30, 2002, COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2001

REVENUES. Net revenues for the three months ended September 30, 2002 increased by \$0.6 million, or 29%, to \$2.7 million from \$2.1 million for the comparable period in 2001.

During the three months ended September 30, 2002, refractive products revenues increased \$0.4 million, or 23%, to \$2.5 million from \$2.1 million for the comparable period in 2001. This revenue increase was primarily the result of increased sales of our excimer laser systems and the recent introduction of our AstraMax diagnostic workstation. During the three months ended September 30, 2002, excimer laser system sales accounted for approximately \$1.8 million in revenues compared to \$1.6 million in revenues over the same period in 2001. During the three months ended September 30, 2002, eight laser systems were sold compared to six laser systems sold during the comparable period in 2001.

Net revenues from patent services for the three months ended September 30, 2002 increased approximately \$0.1 million, or 211%, to \$0.2 million from \$0.1 million for the comparable period in 2001, due to non-exclusive license agreements we entered into in late 2001 and early 2002.

COST OF REVENUES; GROSS PROFIT. For the three months ended September 30, 2002 and 2001, gross profit margins were 48% and 35%, respectively. The gross margin increase during the three months ended September 30, 2002 was primarily attributable to increased sales and decreased overhead. There was a decrease in general overhead expenses of \$0.3 million from the comparable period in 2001.

RESEARCH, DEVELOPMENT AND REGULATORY EXPENSES. Research, development and regulatory expenses for the three months ended September 30, 2002 decreased

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

approximately \$0.5 million, or 71%, to \$0.2 million from \$0.7 million for the comparable period in 2001. While decreasing our expenses, we continued to develop our AstraMax diagnostic workstation and excimer laser systems and continued to pursue protocols in our effort to attain and expand our FDA approvals for our refractive products. If we have sufficient funds, we expect research and development expenses during the remainder of 2002 to be at similar levels and we expect regulatory expenses will remain constant as a result of our continued pursuit of various FDA approvals, including pre-market approval supplements, and the possible development of additional pre-market approval supplements and future protocols for submission to the FDA. The FDA has recently instituted a fee structure that will increase the cost of pursuing new or supplemental approvals.

OTHER GENERAL AND ADMINISTRATIVE EXPENSES. Other general and administrative expenses for the three months ended September 30, 2002 decreased \$2.8 million, or 53%, to \$2.5 million from \$5.3 million for the comparable period in 2001. This decrease was primarily due to a decrease in expenses incurred at our refractive products subsidiary of approximately \$2.9 million that resulted from cost reductions associated with the sales and marketing, customer support and professional services departments of \$1.2 million, a reduction of approximately \$0.5 million in our provision for bad debts, reduced administrative costs of approximately \$0.4 million, \$0.5 million in cost reductions in other departments and \$0.3 million of reductions in our European operation.

SELLING-RELATED EXPENSES. Selling-related expenses consist of those items directly related to sales activities, including commissions on sales, royalty or license fees, warranty expenses, and costs of shipping and installation. Commissions and royalties, in particular, can vary significantly from sale to sale or period to period depending on the location and terms of each sale. Selling-related expenses for the three months ended September 30, 2002 decreased \$0.3 million, or 27%, to \$0.7 million from \$1.0 million during the comparable period in 2001. This decrease was primarily attributable to a \$0.1 million decrease in sales commissions resulting from a higher percentage of sales to distributors net of commissions and a decrease of \$0.2 million of warranty expense primarily related to the terms of laser system sales.

AMORTIZATION OF INTANGIBLES. During the three months ended September 30, 2002, costs relating to the amortization of intangible assets were unchanged from the comparable period in 2001. Items directly related to the amortization of intangible assets are acquired technologies, patents and license agreements.

LOSS FROM OPERATIONS. The operating loss for the three months ended September 30, 2002 was \$2.2 million compared to the operating loss of \$6.4 million for the same period in 2001. This decrease in the loss from operations was primarily due to our improved revenues and gross profit and reductions in operating expenses.

OTHER INCOME AND EXPENSES. Interest and dividend income for the three months ended September 30, 2002 was approximately \$69,000, a decrease of approximately \$55,000 from the comparable period in 2001. Interest and dividend income was earned from the investment of cash and cash equivalents and the collection of long-term receivables related to laser system sales. Interest expense for the three months ended September 30, 2002 was approximately \$142,000, similar to the comparable period in 2001. Other expenses for the three months ended September 30, 2002 include \$140,000 related to the settlement of litigation with a former shareholder of The Farris Group (TFG).

INCOME TAXES. For the three months ended September 30, 2002 and 2001, LaserSight had no income tax expense.

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

DISCONTINUED OPERATIONS. Costs related to the discontinued operation of the health care services segment were approximately \$93,000 during the three months ended September 30, 2001.

NET LOSS. Net loss for the three months ended September 30, 2002, was \$2.5 million compared to a net loss of \$6.5 million for the comparable period in 2001. The decrease in net loss for the three months ended September 30, 2002 can be attributed to our improved revenues and gross profit and the significant reductions in our operating expenses.

LOSS PER SHARE. The loss per basic and diluted share was \$0.09 for the three months ended September 30, 2002 and \$0.25 for the comparable period in

14

2001. Since September 30, 2001, the weighted average shares of common stock outstanding increased primarily due to the conversion of preferred stock during May 2002.

NINE MONTHS ENDED SEPTEMBER 30, 2002, COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2001

REVENUES. Net revenues for the nine months ended September 30, 2002 decreased by \$2.9 million, or 30%, to \$6.6 million from \$9.5 million for the comparable period in 2001.

During the nine months ended September 30, 2002, refractive products revenues decreased \$3.4 million, or 37%, to \$5.8 million from \$9.2 million for the comparable period in 2001. This revenue decrease was primarily the result of decreased sales of our excimer laser systems. During the nine months ended September 30, 2002, excimer laser system sales accounted for approximately \$3.9 million in revenues compared to \$8.0 million in revenues over the same period in 2001. During the nine months ended September 30, 2002, 18 laser systems were sold compared to 29 laser systems sold during the comparable period in 2001.

Net revenues from patent services for the nine months ended September 30, 2002 increased approximately \$0.5 million, or 171%, to \$0.8 million from \$0.3 million for the comparable period in 2001, due to non-exclusive license agreements we entered into in late 2001 and early 2002.

COST OF REVENUES; GROSS PROFIT. For the nine months ended September 30, 2002 and 2001, gross profit margins were 42% and 49%, respectively. The gross margin decrease during the nine months ended September 30, 2002 was primarily attributable to decreased sales and lower average selling prices of the LaserScan LSX excimer laser system, causing overhead to be a higher percentage of sales. The decreased number of laser sales resulted in a decrease in general overhead expenses of \$0.7 million from the comparable period in 2001.

RESEARCH, DEVELOPMENT AND REGULATORY EXPENSES. Research, development and regulatory expenses for the nine months ended September 30, 2002 decreased approximately \$1.5 million, or 56%, to \$1.1 million from \$2.6 million for the comparable period in 2001. While decreasing our expenses, we continued to develop our AstraMax diagnostic workstation and excimer laser systems and continued to pursue protocols in our effort to attain and expand our FDA approvals for our refractive products. If we have sufficient funds, we expect research and development expenses during the remainder of 2002 to be at levels similar to the third quarter of 2002 and we expect regulatory expenses will also be similar to the third quarter of 2002 as a result of our continued pursuit of various FDA approvals, including pre-market approval supplements, and the possible development of additional pre-market approval supplements and future protocols for submission to the FDA. The FDA has recently instituted a fee

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

structure that will increase the cost of pursuing new or supplemental approvals.

OTHER GENERAL AND ADMINISTRATIVE EXPENSES. Other general and administrative expenses for the nine months ended September 30, 2002 decreased \$8.3 million, or 44%, to \$10.6 million from \$18.9 million for the comparable period in 2001. This decrease was primarily due to a decrease in expenses incurred at our refractive products subsidiary of approximately \$8.3 million that resulted from cost reductions associated with the sales and marketing, customer support and professional services departments of \$3.7 million, \$1.7 million in cost reductions in other departments, \$0.8 million of reductions in our European operation and a reduction of \$2.8 million in legal fees related to patent issues and litigation. The patent litigation, which accounted for a significant portion of those legal fees, was settled in May 2001, and we have experienced a significant decrease in our legal expenses since that time. Conversely, we incurred approximately \$0.7 million in severance costs during the first three quarters of 2002 related to staffing reductions.

SELLING-RELATED EXPENSES. Selling-related expenses consist of those items directly related to sales activities, including commissions on sales, royalty or license fees, warranty expenses, and costs of shipping and installation. Commissions and royalties, in particular, can vary significantly from sale to sale or period to period depending on the location and terms of each sale. Selling-related expenses for the nine months ended September 30, 2002 decreased \$1.5 million, or 40%, to \$2.2 million from \$3.7 million during the comparable period in 2001. This decrease was primarily attributable to a \$0.6 million

15

decrease in sales commissions resulting from lower sales and a higher percentage of sales to distributors net of commissions and a decrease of \$0.8 million of warranty expense primarily related to decreased laser system sales and the terms on those sales.

AMORTIZATION OF INTANGIBLES. During the nine months ended September 30, 2002, costs relating to the amortization of intangible assets decreased \$43,000, or 11%, to \$345,000 from \$388,000 for the comparable period in 2001. This decrease was due to the sale of a patent in March 2001 that had an unamortized book value of approximately \$2.4 million. Items directly related to the amortization of intangible assets are acquired technologies, patents and license agreements.

LOSS FROM OPERATIONS. The operating loss for the nine months ended September 30, 2002 was \$11.6 million compared to the operating loss of \$20.9 million for the same period in 2001. This decrease in the loss from operations was primarily due to reductions in operating expenses that more than offset the decrease in sales and related margins of our excimer laser systems.

OTHER INCOME AND EXPENSES. Interest and dividend income for the nine months ended September 30, 2002 was \$0.2 million, a decrease of \$0.3 million over the comparable period in 2001. Interest and dividend income was earned from the investment of cash and cash equivalents and the collection of long-term receivables related to laser system sales. Interest expense for the nine months ended September 30, 2002 was \$0.4 million, an increase of \$0.1 million over the comparable period in 2001 as a result of our loan transaction with Heller in March 2001. Other income included a net gain, after expenses associated with the sale, of \$4.0 million from the sale of U.S. Patent No. 4,784,135 (Blum Patent) in March 2001. The patent was sold for \$6.5 million and, prior to the sale, had a book value of approximately \$2.4 million. Other expenses for the nine months ended September 30, 2002 include \$140,000 related to the settlement of litigation with a former shareholder of TFG while the nine months ended September 30, 2001 include approximately \$0.6 million in payments related to the

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

settlement of patent litigation.

INCOME TAXES. For the nine months ended September 30, 2002 and 2001, LaserSight had no income tax expense.

DISCONTINUED OPERATIONS. Costs related to the discontinued operation of the health care services segment were approximately \$239,000 during the nine months ended September 30, 2001.

NET LOSS. Net loss for the nine months ended September 30, 2002, was \$11.9 million compared to a net loss of \$17.7 million for the comparable period in 2001. The decrease in net loss for the nine months ended September 30, 2002 can be attributed to the significant reductions in our operating expenses partially offset by the decrease in sales of our excimer laser systems and the gain generated by the sale of the Blum Patent in March 2001.

LOSS PER SHARE. The loss per basic and diluted share was \$0.44 for the nine months ended September 30, 2002 and \$0.72 for the comparable period in 2001. Since September 30, 2001, the weighted average shares of common stock outstanding increased primarily due to the conversion of preferred stock during May 2002 and the issuance of common stock related to our July 2001 financing.

LIQUIDITY AND CAPITAL RESOURCES

LaserSight had approximately \$1.4 million of cash and cash equivalents available, as of November 13, 2002, to fund continuing operations. Definitive agreements relating to the China Transaction were executed in August 2002 and include a commitment by the China-based group to purchase \$10.0 million of lasers and other products over the 12-month period ending August 15, 2003 and an equity investment in LaserSight of \$2.0 million. We started shipping products under this agreement in August 2002 and received the equity investment in October 2002. As a result, our short-term liquidity has improved and our operating results are improving. Management continues undertaking steps as part of a plan to attempt to continue to improve liquidity and operations. These steps include seeking (a) to increase sales; and (b) to control overhead costs and operating expenses.

16

With the new revenues being generated from the China Transaction and projected sales to other customers, management expects LaserSight's cash and cash equivalent balances and funds from operations (which are principally the result of sales and collection of accounts receivable) will be sufficient to meet its anticipated operating cash requirements for the next several months. This expectation is based upon assumptions regarding cash flows and results of operations over the next several months and is subject to substantial uncertainty and risks beyond our control. If these assumptions prove incorrect, the duration of the time period during which LaserSight could continue operations could be materially shorter. We continue to face liquidity and capital resource issues relative to the timing of our accounts receivable collection and the successful completion of new sales compared to our ongoing payment obligations. To continue our operations, we will need to generate increased revenues, collect them and reduce our expenditures relative to our recent history. While we are working to achieve these improved results, we cannot assure you that we will be able to generate increased revenues and collections to offset required cash expenditures. We are currently unable to borrow under our revolving credit facility.

The risks and uncertainties regarding management's expectations are also described under the heading "Risk Factors and Uncertainties--Financial and Liquidity Risks."

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

Our working capital remains positive (approximately \$3.8 million as of the end of October 2002), though the timing of the conversion of our current assets into cash is not totally in our control. For example, we cannot dictate the timing of the collection of our accounts receivable with our customers and converting our inventory into cash is dependent on our ability to generate new sales of our products and collect the sales price in a timely manner. While to date we have been able to negotiate payment terms with our suppliers and other creditors, there is no assurance that we can continue to do so.

Our expectations regarding future working capital requirements and our ability to continue operations are based on various factors and assumptions that are subject to substantial uncertainty and risks beyond our control and no assurances can be given that these expectations will prove correct. The occurrence of adverse developments related to these risks and uncertainties or others could result in LaserSight incurring unforeseen expenses, being unable to generate additional sales, to collect new and outstanding accounts receivable, to control expected expenses and overhead, or to negotiate payment terms with creditors, and we would likely be unable to continue operations. Even if we succeed in our attempt to secure additional funds, we cannot assure you that we will be able to generate increased revenues and collections to offset required cash expenditures in a timely manner.

We have actively sought additional funds through the possible sale of certain company assets or through additional investment or loans, which would provide temporary relief from our current liquidity pressures. We have also actively sought a strategic partner or buyer. We had engaged McColl Partners, investment bankers, to assist us in those efforts. Given the extent of those efforts and the publicity about the China Transaction, it is unlikely that there will be any other buyer, strategic partner or investor in the near future.

Our principal sources of funds have historically been from sales of preferred stock and common stock, sales of subsidiaries and patent rights and, to a lesser extent, our operating cash flows. We issued equity securities totaling approximately \$8.9 million in 1999, \$19.1 million in 2000, \$3.0 million in 2001 and \$2.0 million through November 13, 2002, and received proceeds from the exercise of stock options, warrants and our Employee Stock Purchase Plan of approximately \$10.4 million in 1999, \$85,000 in 2000 and \$67,000 in 2001. In addition, we sold subsidiaries and sold or licensed various patent rights, resulting in proceeds to us of approximately \$11.5 million in 2001 and \$2.9 million through November 13, 2002. We have principally used these capital resources to fund operating losses, working capital requirements, capital expenditures, acquisitions and retirement of debt. At September 30, 2002, we had an accumulated deficit of \$97.7 million.

On March 1, 2001, we completed the sale of the Blum Patent for a cash payment of \$6.4 million, net of related expenses. We retained a non-exclusive

17

royalty free license under the patent, which relates to the use of ultraviolet light for the removal of organic tissue. Our net book value of the patent at the date of the sale was approximately \$2.4 million.

On March 12, 2001, we established a \$3.0 million term loan and \$10.0 million revolving credit facility with Heller. We borrowed \$3.0 million under the term loan at an annual rate equal to two and one-half percent (2.5%) above the prime rate. Interest is payable monthly and the loan must be repaid on March 12, 2003. As of November 13, 2002, the outstanding principal on our term loan is approximately \$2.2 million. Under the credit facility, we have the option to borrow amounts at an annual rate equal to one and one-quarter percent (1.25%)

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

above the prime rate for short-term working capital needs or such other purposes as may be approved by Heller. Borrowings are limited to 85% of eligible accounts receivable related to U.S. sales. Eligible accounts receivable will primarily be based on future U.S. sales, which are not expected to increase as a result of our decision to not actively market our laser in the U.S. until we receive additional FDA approvals. See "Industry and Competitive Risks--We do not intend to continue actively marketing our LaserScan LSX laser system in the U.S. until we receive additional FDA approvals." At the present time, we do not have the ability to borrow under the credit facility. Borrowings under the loans are secured by substantially all of the Company's assets. The term loan and credit facility require us to meet certain covenants, including the maintenance of a minimum net worth. The terms of the loans extend to March 12, 2003. In addition to the costs and fees associated with the transaction, we issued to Heller a warrant to purchase 243,750 shares of common stock at an exercise price of \$3.15 per share. The warrant expires on March 12, 2004. On August 15, 2002, Heller provided a waiver of our prior defaults under our loan agreement pending the funding of the equity portion of the China Transaction. Upon receipt of the equity investment in October 2002, revised covenants became effective that decreased the required minimum level of net worth to \$2.1 million, decreased minimum tangible net worth to negative \$2.8 million and decreased minimum quarterly revenues during the last two quarters of 2002 and the first quarter of 2003. In exchange for the waiver and revised covenants, the Company paid \$150,000 in principal to Heller upon the receipt of the equity investment in October 2002 and agreed to increase other monthly principal payments to \$60,000 in October 2002 and \$40,000 during each of November and December 2002 and January 2003, with the remaining principal due on March 12, 2003.

In July 2001, we completed a \$3.0 million private placement of series F convertible participating preferred stock.

On April 16, 2002, the Company announced that it had entered into a letter of intent and a non-exclusive license with a third party contemplating the sale of patents and technology related to its AstraMax diagnostic workstation product. On May 14, 2002, the Company announced the transaction had been terminated. The third party has alleged that the Company violated the terms of the non-exclusive license. The Company denies any intent to do so. Prior to the termination of the process, the Company received cash payments totaling \$875,000. In May 2002, the Company settled the dispute with the third party by granting that third party a license to the Company's `504 Scanning Patent.

Our working capital decreased \$11.3 million from \$13.9 million at December 31, 2001 to \$2.6 million as of September 30, 2002. This decrease in working capital resulted primarily from the net loss of \$11.9 million and the classification of our term loan with Heller in current liabilities as of March 12, 2002.

Operating activities used net cash of \$1.8 million during the nine months ended September 30, 2002, compared to \$15.8 million during the same period in 2001, and \$17.7 million during the year ended December 31, 2001. We expect to incur a loss and a deficit in cash flow from operations for the last quarter of 2002. There can be no assurance that we can achieve profitability or positive operating cash flow in any subsequent fiscal period. Net cash used by investing activities of \$4,437 during the nine months ended September 30, 2002, can be attributed to purchases of property and equipment. As of September 30, 2002, we had no significant commitments for capital expenditures. There was \$0.5 million net cash used in financing activities during the nine months ended September 30, 2002, primarily representing principal payments on the term loan to Heller.

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

underlying our business plan or our expectations regarding our working capital requirements or our ability to continue operations.

Our ability to continue operations is based on factors including: the success of our sales efforts in China and in Europe where our efforts will initially be primarily focused, the uncertain timing of additional supplemental FDA approvals for our LaserScan LSX excimer laser system (which has resulted in our decision to not actively market our laser system in the U.S. until additional FDA approvals are received), potential growth in laser sales after receipt of further FDA approvals, increases in accounts receivable and inventory purchases when sales increase, our present inability to borrow under our revolving credit facility, the uncertain impact of the market introduction of our UltraShaper durable keratomes and AstraMax diagnostic workstations, and the absence of unanticipated product development and marketing costs. See "Risk Factors and Uncertainties--Industry and Competitive Risks--We cannot assure you that our keratome products will achieve market acceptance" and "--We do not intend to continue actively marketing our LaserScan LSX laser system in the U.S. until we receive additional FDA approvals."

RISK FACTORS AND UNCERTAINTIES

The business, results of operations and financial condition of LaserSight and the market price of our common stock may be adversely affected by a variety of factors, including the ones noted below:

FINANCIAL AND LIQUIDITY RISKS

WE HAVE EXPERIENCED SIGNIFICANT LOSSES AND OPERATING CASH FLOW DEFICITS AND WE EXPECT THAT OPERATING CASH FLOW DEFICITS WILL CONTINUE.

We continue to be challenged by our significant liquidity and capital resource issues relative to the timing of our accounts receivable collection and the successful completion of new sales compared to our ongoing payment obligations. We started shipping products related to the China Transaction in August 2002 and received the equity investment portion of the transaction in October 2002. As a result, the Company's short-term liquidity has improved and its operations are improving. We continue undertaking steps as part of a plan to attempt to continue to improve liquidity and operations with the goal of sustaining Company operations. These steps include seeking (a) to increase sales; and (b) to control overhead costs and operating expenses.

We will still need to generate increased revenues and collect them. While we are working to achieve these improved results, we cannot assure you that we will be able to generate increased revenues and collections to fund required cash expenditures in a timely manner.

Our working capital remains positive (approximately \$3.8 million as of the end of October 2002), though the timing of the conversion of our current assets into cash is not totally in our control. For example, we cannot dictate the timing of the collection of our accounts receivable with our customers and converting our inventory into cash is dependent on our ability to generate new sales with our products and collect the sales price in a timely manner.

We experienced significant net losses and deficits in cash flow from operations for the years ended December 31, 2001 and 2000 and the nine months ended September 30, 2002, as set forth in the following table. We cannot be certain that we will be able to achieve or sustain profitability or positive operating cash flow in the future.

	Year Ended December 31,	Nine months Ended
	2000	September 30,
	2001	2002

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

	----	----	----
Net loss	\$21.4 million	\$26.2 million	\$11.9 million
Deficit in cash flow from operations	\$15.7 million	\$17.7 million	\$ 1.8 million

19

In the longer term, our expectations are based on additional factors including: the success of our sales efforts in China and in Europe where our efforts will initially be primarily focused, the uncertain timing of additional supplemental FDA approvals for our LaserScan LSX excimer laser system (which has resulted in our decision to not actively market our laser system in the U.S. until additional FDA approvals are received), potential growth in laser sales after receipt of further FDA approvals, increases in accounts receivable and inventory purchases when sales increase, our present inability to borrow under our revolving credit facility, the uncertain impact of the market introduction of our UltraShaper durable keratomes and AstraMax diagnostic workstations, and the absence of unanticipated product development and marketing costs. These factors and assumptions are subject to substantial uncertainty and risks beyond our control and no assurances can be given that these expectations will prove correct. These risks and uncertainties include:

- o the willingness of trade creditors to continue to extend credit to LaserSight;
- o reductions and cancellations in orders;
- o our ability to fulfill orders in light of our current financial condition;
- o our ability to sell products and collect accounts receivables at or above the level of management's expectations;
- o the occurrence of unforeseen expenses and our ability to control expected expenses and overhead;
- o the occurrence of property and casualty losses which are uninsured or that generate insurance proceeds that cannot be collected in a short time frame;
- o our ability to improve pricing and terms of international sales;
- o the loss of, or failure to obtain additional, customers; and
- o changes in pricing by our competitors.

With respect to management's expectations regarding LaserSight's ability to continue operations for the expected period and the risks and uncertainties relating to those expectations, readers are encouraged to review the discussions under the captions "Management's Discussion and Analysis of Financial Condition and Results of Operations--Liquidity and Capital Resources" and "--Risk Factors and Uncertainties--," including "--If our uncollectible receivables exceed our reserves we will incur additional unanticipated expenses, and we may experience difficulty collecting restructured receivables with extended payment terms," "--We do not intend to continue actively marketing our LaserScan LSX laser system in the U.S. until we receive additional FDA approvals," "--Required per procedure fees payable to Visx under our license agreement may exceed per procedure fees collected by us," "--Our supply of certain critical components and systems may be interrupted because of our reliance on a limited number of suppliers," as well as Note 1 of our Notes to Condensed Consolidated Financial Statements for the nine months ended September 30, 2002. These risks and uncertainties can affect LaserSight's ability to continue operations for the expected period in the absence of obtaining additional capital resources.

IF OUR UNCOLLECTIBLE RECEIVABLES EXCEED OUR RESERVES WE WILL INCUR ADDITIONAL UNANTICIPATED EXPENSES, AND WE MAY EXPERIENCE DIFFICULTY COLLECTING RESTRUCTURED RECEIVABLES WITH EXTENDED PAYMENT TERMS.

Although we monitor the status of our receivables and maintain a reserve

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

for estimated losses, we cannot be certain that our reserves for estimated losses, which were approximately \$5.8 million at September 30, 2002, will be sufficient to cover the amount of our actual write-offs over time. At September 30, 2002, our net trade accounts and notes receivable totaled approximately \$8.8 million, and accrued commissions, the payment of which generally depends on the collection of such net trade accounts and notes receivable, totaled approximately \$1.8 million. Actual write-offs that exceed amounts reserved could have a material adverse effect on our consolidated financial condition and results of operations. The amount of any loss that we may have to recognize in connection with our inability to collect receivables is principally dependent on our customers' ongoing financial condition, their ability to generate revenues from our laser systems, and our ability to obtain and enforce legal judgments against delinquent customers.

20

Our ability to evaluate the financial condition and revenue-generating ability of our prospective customers located outside of the U.S., and our ability to obtain and enforce legal judgments against customers located outside of the U.S., is generally more limited than for our customers located in the U.S. Our agreements with our international customers typically provide that the contracts are governed by Florida law. We have not determined whether or to what extent courts or administrative agencies located in foreign countries would enforce our right to collect such receivables or to recover laser systems from customers in the event of a customer's payment default. When a customer is not paying according to established terms, we attempt to communicate and understand the underlying causes and work with the customer to resolve any issues we can control or influence. In most cases, we have been able to resolve the customer's issues and continue to collect our receivable, either on the original schedule or under restructured terms. If such issues are not resolved, we evaluate our legal and other alternatives based on existing facts and circumstances. In most such cases, we have concluded that the account should be written off as uncollectible.

INDUSTRY AND COMPETITIVE RISKS

The following Industry and Competitive Risks relate primarily to the longer term.

WE DO NOT INTEND TO CONTINUE ACTIVELY MARKETING OUR LASERSCAN LSX LASER SYSTEM IN THE U.S. UNTIL WE RECEIVE ADDITIONAL FDA APPROVALS.

We received the FDA approval necessary for the commercial marketing and sale of our LaserScan LSX excimer laser system in the U.S. in late 1999 and commercial shipments to customers in the U.S. began in March 2000. To date, our LaserScan LSX laser system and per procedure fee business model have not achieved a level of market acceptance sufficient to provide our cash flows from operations to fund our business. As a result of our current liquidity and capital resource issues, we have decided to focus on international markets, primarily China with our LaserScan LSX laser system and Europe with a custom ablation product line, and not to continue actively marketing our laser system in the U.S. until we receive additional FDA approvals.

The current level of per procedure fees payable to us by existing refractive surgeon customers in the U.S. may not continue to be accepted by the marketplace or may exceed those charged by our competitors. If our competitors reduce or do not charge per procedure fees to users of their systems, we could be forced to reduce or eliminate the fees charged under this business model, which could significantly reduce our revenues. For example, Nidek Co., Ltd., one of our competitors, has publicly stated that it will not charge per procedure fees to users of its laser systems in the U.S. or internationally. See also

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

"--Company and Business Risks--Required per procedure fees payable to Visx under our license agreement may exceed per procedure fees collected by us."

WE CANNOT ASSURE YOU THAT OUR KERATOME PRODUCTS WILL ACHIEVE MARKET ACCEPTANCE.

Keratomes are surgical devices used to create a corneal flap immediately prior to LASIK laser vision correction procedures. We began to roll out our MicroShape family of keratome products with the commercial launch of our UltraEdge keratome blades in July 1999 and of our UniShaper single-use keratomes and control consoles in December 1999. In November 2001, we commercially released our UltraShaper durable keratomes after a thorough process of engineering refinement and validity testing. In order for our UniShaper single-use keratome to be commercially viable it will need to be reengineered, if possible, to include most or all of the features included in our UltraShaper keratome. Our UltraShaper durable keratome incorporates the features found in the ACS keratome previously marketed by Bausch & Lomb, Inc. with new enhancements and features. However, Bausch & Lomb has not aggressively marketed or serviced the ACS since 1997 when we licensed the rights to commercially market keratomes based on the same technology, and has successfully transitioned a large number of refractive surgeons from the ACS to its Hansatome durable keratome product. We believe that many refractive surgeons learned to perform the LASIK procedure using the ACS and prefer the surgical technique required by

21

the ACS, which is also used to operate our UltraShaper durable keratome, to the surgical technique required to operate the Hansatome keratome product. However, we cannot assure you that we will be successful in commercially introducing or achieving broad market acceptance of our UltraShaper durable keratome or our other keratome products.

If we cannot successfully market and sell our keratome products or if we are unable to successfully find a marketing and distribution alliance with another company, we may not be able to execute our business plan, which would have a material adverse effect on our business, financial condition and results of operations. See also "--Company and Business Risks--Required minimum payments under our keratome license agreement may exceed our gross profits from sales of our keratome products."

THE VISION CORRECTION INDUSTRY CURRENTLY CONSISTS OF A FEW ESTABLISHED PROVIDERS WITH SIGNIFICANT MARKET SHARES AND WE ARE ENCOUNTERING DIFFICULTIES COMPETING IN THIS HIGHLY COMPETITIVE ENVIRONMENT.

The vision correction industry is subject to intense, increasing competition, and we do not know if we will be able to compete successfully against our current and future competitors. Many of our competitors have established products, distribution capabilities and customer service networks in the U.S. marketplace, are substantially larger and have greater brand recognition and greater financial and other resources than we do. Visx, the historical industry leader for excimer laser system sales in the U.S., sold laser systems that performed a significant majority of the laser vision correction procedures performed in the U.S. in 1999, 2000 and 2001. Similarly, Bausch & Lomb sold a significant majority of the keratomes used by refractive surgeons in the U.S. in 1999, 2000 and 2001. In 2000, Alcon acquired Summit Autonomous Inc. The merger resulted in a combined entity with enhanced market presence, technology base and distribution capabilities and provided Alcon with a narrow beam laser technology platform that will compete more directly with our precision beam, scanning microspot LaserScan LSX excimer laser system. In addition, as a result of the acquisition, the combined entity will be able to sell narrow beam laser systems under a royalty-free license to certain Visx

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

patents without incurring the expense and uncertainty associated with intellectual property litigation with Visx. We anticipate that Alcon will leverage the sale of its laser systems with its other ophthalmic products. Competitors are using our weak financial condition as a reason why a buyer shouldn't buy our laser.

MANY OF OUR COMPETITORS RECEIVED EARLIER REGULATORY APPROVALS THAN US AND MAY HAVE A COMPETITIVE ADVANTAGE OVER US DUE TO THE SUBSEQUENT EXPANSION OF THEIR REGULATORY APPROVALS AND THEIR SUBSTANTIAL EXPERIENCE IN THE U.S. MARKET.

We received the FDA approval necessary for the commercial sale of our LaserScan LSX excimer laser system in the U.S. in November 1999 and commercial shipments to customers in the U.S. began in March 2000. Our direct competitors include large corporations such as Visx and Alcon, each of whom received FDA approval of excimer laser systems more than three years prior to our approval and has substantial experience manufacturing, marketing and servicing laser systems in the U.S. In addition to Visx and Alcon, Nidek and Bausch & Lomb have also received FDA approval for their laser systems.

In the U.S., a manufacturer of excimer laser vision correction systems gains a competitive advantage by having its systems approved by the FDA for a wider range of treatments. Initial FDA approvals of excimer laser vision correction systems historically have been limited to the treatment of low to moderate nearsightedness, with additional approvals for other and broader treatments granted only as a result of subsequent FDA applications and clinical trials. Our LaserScan LSX is currently approved for the LASIK treatment of nearsightedness with and without astigmatism for a range of treatment of refractive errors up to -6.0 diopters MRSE with or without a refractive astigmatism up to 4.5 diopters and the PRK treatment of low to moderate nearsightedness (up to -6.0 diopters) without astigmatism. Additionally, we have received FDA approval to operate our laser systems at a 200 Hz pulse repetition rate, twice the originally approved rate. We have submitted PMA supplements to the FDA to permit our laser systems sold to customers in the U.S. to utilize LASIK to treat hyperopia, hyperopic astigmatism and mixed astigmatism. FDA approval of these applications is anticipated in 2002, though we cannot ensure

22

if or when the approval will be received. Our ability to sell our laser systems in the U.S. may be severely impaired if the FDA does not give timely approval to these supplements.

Currently, excimer laser vision correction systems manufactured by Visx, Alcon, Bausch & Lomb and Nidek have been approved for higher levels of nearsightedness than the LaserScan LSX. Alcon's Apex Plus and Ladarvision Excimer Laser Workstations, Visx's Star S2 Excimer Laser System and Nidek's EC-5000 Excimer Laser System have received FDA approval for the LASIK treatment of nearsightedness with or without astigmatism. The approvals for many of the systems are for the correction of nearsightedness in the range of 0 diopters to -14.0 diopters and nearsightedness with astigmatism generally in the range of -0.5 diopters to -5.0 diopters. Bausch & Lomb's Technolas 217 excimer laser has also received FDA approval for the treatment of nearsightedness from -1.0 diopter up to -7.0 diopters with up to -3.0 diopters of astigmatism. The Visx and Alcon excimer laser systems are also approved for the treatment of moderate farsightedness. In September 2000, the FDA approved Alcon's Ladarvision system for the correction using LASIK of farsightedness of up to +6.0 diopters and an astigmatism range of up to 6.0 diopters. In October 2000, the FDA approved Visx's Star S2 and S3 systems for the correction using PRK of farsightedness of up to +5.0 diopters and an astigmatism range of up to 3.0 diopters. In February 2001, the FDA approved of Visx's Custom-Contoured Ablation Pattern Method for treatment of decentered ablations under a Humanitarian Device Exemption (HDE).

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

An HDE authorizes the use and marketing of a device that is intended to benefit patients in the treatment of conditions that affect fewer than 4,000 individuals. In August 2002, Alcon announced the approval of its wavefront-guided laser eye surgery application for the treatment of myopia between zero and -7.0 diopters. Competitors' earlier receipt of LASIK and hyperopia-specific FDA regulatory approvals could give them a significant competitive advantage that could impede our ability to successfully sell our LaserScan LSX system in the U.S. Our failure to successfully market our product could have a material adverse effect on our business, financial condition and results of operations.

All of our principal competitors in the keratome business, including current market leader Bausch & Lomb, received FDA clearance prior to the commercialization of our keratome products and have substantial experience marketing their keratome products. The established market presence in the U.S. of previously approved laser systems and keratome products, as well as the entry of new competitors into the market upon receipt of new or expanded regulatory approvals, could impede our ability to successfully introduce our LaserScan LSX system in the U.S. and our keratome products worldwide and may have a material adverse effect on our business, financial condition and results of operations.

WE DEPEND UPON OUR ABILITY TO ESTABLISH AND MAINTAIN STRATEGIC RELATIONSHIPS.

We believe that our ability to establish and maintain strategic relationships will have a significant impact on our ability to meet our business objectives. These strategic relationships are critical to our future success because we believe that these relationships will help us to:

- o extend the reach of our products to a larger number of refractive surgeons;
- o develop and deploy new products;
- o further enhance the LaserSight brand; and
- o generate additional revenue.

Entering into strategic relationships is complicated because some of our current and future strategic partners may decide to compete with us in some or all of our markets. In addition, we may not be able to establish relationships with key participants in our industry if they have relationships with our competitors, or if we have relationships with their competitors. Moreover, some potential strategic partners have resisted, and may continue to resist, working with us until our products and services have achieved widespread market acceptance. Once we have established strategic relationships, we will depend on our partners' ability to generate increased acceptance and use of our products and services. To date, we have established only a limited number of strategic relationships, and many of these relationships are in the early stages of development. There can be no assurance as to the terms, timing or consummation of any future strategic relationships. If we lose any of these strategic

23

relationships or fail to establish additional relationships, or if our strategic relationships fail to benefit us as expected, we may not be able to execute our business plan, and our business will suffer.

BECAUSE THE SALE OF OUR PRODUCTS IS DEPENDENT ON THE CONTINUED MARKET ACCEPTANCE OF LASER-BASED REFRACTIVE EYE SURGERY USING THE LASIK PROCEDURE, THE LACK OF BROAD MARKET ACCEPTANCE WOULD HURT OUR BUSINESS.

We believe that whether we achieve profitability and growth will depend, in part, upon the continued acceptance of laser vision correction using the LASIK

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

procedure in the U.S. and other countries. We cannot be certain that laser vision correction will continue to be accepted by either the refractive surgeons or the public at large as an alternative to existing methods of treating refractive vision disorders. The acceptance of laser vision correction and, specifically, the LASIK procedure may be adversely affected by:

- o possible concerns relating to safety and efficacy, including the predictability, stability and quality of results;
- o the public's general resistance to surgery;
- o the effectiveness and lower cost of alternative methods of correcting refractive vision disorders;
- o the lack of long-term follow-up data;
- o the possibility of unknown side effects;
- o the lack of third-party reimbursement for the procedures;
- o the cost of the procedure; and
- o unfavorable publicity involving patient outcomes from the use of laser vision correction.

Unfavorable side effects and potential complications that may result from the use of laser vision correction systems manufactured by any manufacturer may broadly affect market acceptance of laser-based vision correction surgery. Potential patients may not distinguish between our precision beam scanning spot technology and the laser technology incorporated by our competitors in their laser systems, and customers may not differentiate laser systems and procedures that have not received FDA approval from FDA-approved systems and procedures. Any adverse consequences resulting from procedures performed with a competitor's systems or an unapproved laser system could adversely affect consumer acceptance of laser vision correction in general. In addition, because laser vision correction is an elective procedure that is not typically covered by insurance and involves more significant immediate expense than eyeglasses or contact lenses, adverse changes in the U.S. or international economy may cause consumers to reassess their spending choices and to select lower-cost alternatives for their vision correction needs. Any such shift in spending patterns could reduce the volume of LASIK procedures performed that would, in turn, reduce the number of laser systems sold and our revenues from per procedure fees and sales of single-use products such as our UltraEdge keratome blades.

The failure of laser vision correction to achieve continued market acceptance could have a material adverse effect on our business prospects. Even if laser vision correction achieves and sustains market acceptance, sales of our keratome products could be adversely impacted if a laser procedure that does not require the creation of a corneal flap were to emerge as the procedure of choice.

NEW PRODUCTS OR TECHNOLOGIES COULD ERODE DEMAND FOR OUR PRODUCTS OR MAKE THEM OBSOLETE, AND OUR BUSINESS COULD BE HARMED IF WE CANNOT KEEP PACE WITH ADVANCES IN TECHNOLOGY.

In addition to competing with eyeglasses and contact lenses, excimer laser vision correction competes or may compete with newer technologies such as intraocular lenses, intracorneal inlays, corneal rings and surgical techniques using different or more advanced types of lasers. Two products that may become competitive within the near term are implantable contact lenses, which are pending FDA approval, and corneal rings, which have been approved by the FDA. Both of these products require procedures with lens implants, and their ultimate market acceptance is unknown at this time. To the extent that any of these or other new technologies are perceived to be clinically superior or economically

more attractive than currently marketed excimer laser vision correction

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

procedures or techniques, they could erode demand for our excimer laser and keratome products, cause a reduction in selling prices of such products or render such products obsolete. In addition, if one or more competing technologies achieves broader market acceptance or renders laser vision correction procedures obsolete, it would have a material adverse effect on our business, financial condition and results of operations.

As is typical in the case of new and rapidly evolving industries, the demand and market for recently introduced products and technologies is uncertain, and we cannot be certain that our LaserScan LSX laser system, UltraShaper durable keratome, UltraEdge keratome blades, UniShaper single-use keratome or future new products and enhancements will be accepted in the marketplace. In addition, announcements or the anticipation of announcements of new products, whether for sale in the near future or at some later date, may cause customers to defer purchasing our existing products.

If we cannot adapt to changing technologies, our products may become obsolete, and our business could suffer. Our success will depend, in part, on our ability to continue to enhance our existing products, develop new technology that addresses the increasingly sophisticated needs of our customers, license leading technologies and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using new technologies effectively or adapting our proprietary technology to evolving customer requirements or emerging industry standards.

ADDITIONAL COMPANY AND BUSINESS RISKS

The following Additional Company and Business Risks relate primarily to the longer term.

THE LOSS OF KEY PERSONNEL COULD ADVERSELY AFFECT OUR BUSINESS.

Our ability to maintain our competitive position depends in part upon the continued contributions of our executive officers and other key employees, especially Michael R. Farris, our president and chief executive officer. A loss of one or more such officers or key employees could have a material adverse effect on our business. We do not carry "key person" life insurance on any officer or key employee.

Our staff reductions during 2001 and to date in 2002 may have a negative impact on our ability to attract and retain personnel. If we fail to attract and retain qualified individuals for necessary positions, it could have a material adverse effect on our business, financial condition and results of operations.

WE HAVE MOVED ALL INTERNATIONAL MANUFACTURING OPERATIONS FROM COSTA RICA TO THE U.S. AND MUST CONTINUE TO COMPLY WITH STRINGENT REGULATION OF OUR MANUFACTURING OPERATIONS.

We moved the manufacturing location our laser systems for sale in international markets to our U.S. location from our manufacturing facility in Costa Rica. We cannot assure you that we will not encounter difficulties in increasing our production capacity for our laser systems at our Florida facility, including problems involving production delays, quality control or assurance, component supply and lack of qualified personnel. Any products manufactured or distributed by us pursuant to FDA clearances or approvals are subject to extensive regulation by the FDA, including record-keeping requirements and reporting of adverse experience with the use of the product. Our manufacturing facilities are subject to periodic inspection by the FDA, certain state agencies and international regulatory agencies. We require that our key suppliers comply with recognized standards as well as our own quality

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

standards, and we regularly test the components and sub-assemblies supplied to us. Any failure by us or our suppliers to comply with applicable regulatory requirements, including the FDA's quality systems/good manufacturing practice (QSR/GMP) regulations, could cause production and distribution of our products to be delayed or prohibited, either of which could have a material adverse effect on our business, financial condition and results of operations.

25

REQUIRED PER PROCEDURE FEES PAYABLE TO VISX UNDER OUR LICENSE AGREEMENT MAY EXCEED PER PROCEDURE FEES COLLECTED BY US.

In addition to the risk that our refractive lasers will not be accepted in the marketplace, we are required to pay Visx a royalty for each procedure performed in the U.S. using our refractive lasers. The required per procedure fees we are required to pay to Visx may exceed the per procedure fees we are able to charge and/or collect from refractive surgeons, which could result in a material adverse effect on our financial condition and results of operations.

REQUIRED MINIMUM PAYMENTS UNDER OUR KERATOME LICENSE AGREEMENT MAY EXCEED OUR GROSS PROFITS FROM SALES OF OUR KERATOME PRODUCTS.

We are required to make certain minimum payments to the licensor under our keratome license agreement that was amended and restated on January 4, 2001. This amendment replaced a January 18, 2000 amendment in its entirety. Under the terms of the amendment we issued 730,552 shares of common stock to the licensors, valued at approximately \$1.1 million, in partial payment for royalties during the term of the license. The term of the license was extended three years until July 31, 2005. In addition, remaining minimum royalty payments totaling approximately \$4.1 million as of November 13, 2002 will be due in monthly installments (averaging approximately \$150,000 per month through 2003) or quarterly installments (averaging approximately \$238,000 per quarter from January 2004 through October 2005) through the term of the amendment. As a result of our obligations under this license arrangement, the minimum royalty payments we are required to make to the licensors may exceed our gross profits from sales of our UniShaper and UltraShaper keratome products. The amendment eliminated a restriction on us manufacturing, marketing and selling other keratomes, but the sale of other keratomes will be included in the gross profit to be shared with the licensors. The licensor's share of the gross profit, as defined in the amendment, decreased from 50% to 10%.

OUR FAILURE TO TIMELY OBTAIN OR EXPAND REGULATORY APPROVALS FOR OUR PRODUCTS AND TO COMPLY WITH REGULATORY REQUIREMENTS COULD ADVERSELY AFFECT OUR BUSINESS.

Our excimer laser systems, diagnostic and custom ablation products and keratome products are subject to strict governmental regulations that materially affect our ability to manufacture and market these products and directly impact our overall business prospects. FDA regulations impose design and performance standards, labeling and reporting requirements, and submission conditions in advance of marketing for all medical laser products in the U.S. New product introductions, expanded treatment types and levels for approved products, and significant design or manufacturing modifications require a premarket clearance or approval by the FDA prior to commercialization in the U.S. The FDA approval process, which is lengthy and uncertain, requires supporting clinical studies and substantial commitments of financial and management resources. Failure to obtain or maintain regulatory approvals and clearances in the U.S. and other countries, or significant delays in obtaining these approvals and clearances, could prevent us from marketing our products for either approved or expanded indications or treatments, which could substantially decrease our future revenues.

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

In March 2002, we pursued a "real time" PMA supplement seeking approval for the use of our advanced adaptive eye tracking system in an accelerated time frame, as few as 30 days. In April 2002, we were advised by the FDA that they would review the submission in a 180-day timeframe. We are currently in the process of addressing the FDA's questions related to this submission.

Additionally, product and procedure labeling and all forms of promotional activities are subject to examination by the FDA, and current FDA enforcement policy prohibits the marketing by manufacturers of approved medical devices for unapproved uses. Noncompliance with these requirements may result in warning letters, fines, injunctions, recall or seizure of products, suspension of manufacturing, denial or withdrawal of PMAs, and criminal prosecution. Laser products marketed in foreign countries are often subject to local laws governing health product development processes, which may impose additional costs for overseas product development. Future legislative or administrative requirements,

26

in the U.S. or elsewhere, may adversely affect our ability to obtain or retain regulatory approval for our products. The failure to obtain approvals for new or additional uses on a timely basis could have a material adverse effect on our business, financial condition and results of operations.

OUR BUSINESS DEPENDS ON OUR INTELLECTUAL PROPERTY RIGHTS, AND IF WE ARE UNABLE TO PROTECT THEM, OUR COMPETITIVE POSITION MAY BE ADVERSELY AFFECTED.

Our business plan is predicated on our proprietary systems and technology, including our precision beam scanning microspot technology laser systems. We protect our proprietary rights through a combination of patent, trademark, trade secret and copyright law, confidentiality agreements and technical measures. We generally enter into non-disclosure agreements with our employees and consultants and limit access to our trade secrets and technology. We cannot assure you that the steps we have taken will prevent misappropriation of our intellectual property. Misappropriation of our intellectual property would have a material adverse effect on our competitive position. In addition, we may have to engage in litigation or other legal proceedings in the future to enforce or protect our intellectual property rights or to defend against claims of invalidity. These legal proceedings may consume considerable resources, including management time and attention, which would be diverted from the operation of our business, and the outcome of any such legal proceeding is inherently uncertain.

We are aware that certain competitors are developing products that may potentially infringe patents owned or licensed exclusively by us. In order to protect our rights in these patents, we may find it necessary to assert and pursue infringement claims against such third parties. We could incur substantial costs and diversion of management resources litigating such infringement claims and we cannot assure you that we will be successful in resolving such claims or that the resolution of any such dispute will be on terms that are favorable to us. See "--Patent infringement allegations may impair our ability to manufacture and market our products."

PATENT INFRINGEMENT ALLEGATIONS MAY IMPAIR OUR ABILITY TO MANUFACTURE AND MARKET OUR PRODUCTS.

There are a number of U.S. and foreign patents covering methods and apparatus for performing corneal surgery that we do not own or have the right to use. If we were found to infringe a patent in a particular market, we and our customers may be enjoined from manufacturing, marketing, selling and using the infringing product in the market and may be liable for damages for any past

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

infringement of such rights. In order to continue using such rights, we would be required to obtain a license, which may require us to make royalty, per procedure or other fee payments. We cannot be certain if we or our customers will be successful in securing licenses, or that if we obtain licenses, such licenses will be available on acceptable terms. Alternatively, we might be required to redesign the infringing aspects of these products. Any redesign efforts that we undertake could be expensive and might require regulatory review. Furthermore, the redesign efforts could delay the reintroduction of these products into certain markets, or may be so significant as to be impractical. If redesign efforts were impractical, we could be prevented from manufacturing and selling the infringing products, which would have a material adverse effect on our business, financial condition and results of operations.

Litigation involving patents is common in our industry. While we do not believe our laser systems or keratome products infringe any valid and enforceable patents that we do not own or have a license to, we cannot assure you that one or more of our other competitors or other persons will not assert that our products infringe their intellectual property, or that we will not in the future be deemed to infringe one or more patents owned by them or some other party. We could incur substantial costs and diversion of management resources defending any infringement claims. Furthermore, a party making a claim against us could secure a judgment awarding substantial damages, as well as injunctive or other equitable relief that could effectively block our ability to market one or more of our products. In addition, we cannot assure you that licenses for any intellectual property of third parties that might be required for our products will be available on commercially reasonable terms, or at all.

27

WE ARE SUBJECT TO CERTAIN RISKS ASSOCIATED WITH OUR INTERNATIONAL SALES.

Our international sales accounted for 79% and 73% of our total revenues during the nine months ended September 30, 2002 and the year ended December 31, 2001, respectively. In the future, we expect that sales to U.S. accounts will represent a higher percentage of our total sales only when additional regulatory approvals are received for our LaserScan LSX laser system in the U.S. We are presently focusing our sales efforts on international sales in China and Europe.

International sales of our products may be limited or disrupted by:

- o the imposition of government controls;
- o export license requirements;
- o economic or political instability;
- o trade restrictions;
- o difficulties in obtaining or maintaining export licenses;
- o changes in tariffs; and
- o difficulties in staffing and managing international operations.

Our sales have historically been and are expected to continue to be denominated in U.S. dollars. The European Economic Union's conversion to a common currency, the euro, is not expected to have a material impact on our business. However, due to our significant export sales, we are subject to exchange rate fluctuations in the U.S. dollar, which could increase the effective price in local currencies of our products. This could result in reduced sales, longer payment cycles and greater difficulty in collecting receivables relating to our international sales.

OUR SUPPLY OF CERTAIN CRITICAL COMPONENTS AND SYSTEMS MAY BE INTERRUPTED BECAUSE OF OUR RELIANCE ON A LIMITED NUMBER OF SUPPLIERS.

We currently purchase certain components used in the production, operation

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

and maintenance of our laser systems and keratome products from a limited number of suppliers, and certain key components are provided by a single vendor. We are currently seeking a replacement blade manufacturer, and the majority of our UltraShaper components are manufactured exclusively by Owens Industries pursuant to our agreement with them. We do not have long-term contracts with providers of some key laser system components, including TUI Lasertechnik und Laserintegration GmbH, which currently is a single source supplier for the laser heads used in our LaserScan LSX excimer laser system. Currently, SensoMotoric Instruments GmbH, Teltow, Germany, is a single source supplier for the eye tracker boards used in our excimer laser systems. Any interruption in the supply of critical laser or keratome components could have a material adverse effect on our business, financial condition and results of operations. If any of our key suppliers ceases providing us with products of acceptable quality and quantity at a competitive price and in a timely fashion, we would have to locate and contract with a substitute supplier and, in some cases, such substitute supplier would need to be qualified by the FDA. If substitute suppliers cannot be located and qualified in a timely manner or could not provide required products on commercially reasonable terms, it would have a material adverse effect on our business, financial condition and results of operations.

UNLAWFUL TAMPERING OF OUR SYSTEM CONFIGURATIONS COULD RESULT IN REDUCED REVENUES AND ADDITIONAL EXPENSES.

We include a procedure counting mechanism on LaserScan LSX lasers manufactured for sale and use in the U.S. Users of our LaserScan LSX excimer laser system could tamper with the software or hardware configuration of the system so as to alter or eliminate the procedure counting mechanism that facilitates the collection of per procedure fees. Unauthorized tampering with our procedure counting mechanism by users could result in us being required to pay per procedure fees to Visx that we were not able to collect from users. If we are unable to prevent such tampering, our license agreement with Visx could be terminated after all applicable notice and cure periods have expired.

28

INADEQUACY OR UNAVAILABILITY OF INSURANCE MAY EXPOSE US TO SUBSTANTIAL PRODUCT LIABILITY CLAIMS.

Our business exposes us to potential product liability risks and possible adverse publicity that are inherent in the development, testing, manufacture, marketing and sale of medical devices for human use. These risks increase with respect to our products that receive regulatory approval for commercialization. We have agreed in the past, and we will likely agree in the future, to indemnify certain medical institutions and personnel who conduct and participate in our clinical studies. While we maintain product liability insurance, we cannot be certain that any such liability will be covered by our insurance or that damages will not exceed the limits of our coverage. Even if a claim is covered by insurance, the costs of defending a product liability, malpractice, negligence or other action, and the assessment of damages in excess of insurance coverage in the event of a successful product liability claim, could have a material adverse effect on our business, financial condition and results of operations. Further, product liability insurance may not continue to be available, either at existing or increased levels of coverage, on commercially reasonable terms.

COMMON STOCK RISKS

VARIATIONS IN OUR SALES AND OPERATING RESULTS MAY CAUSE OUR STOCK PRICE TO FLUCTUATE.

Our operating results have fluctuated in the past, and may continue to fluctuate in the future, as a result of a variety of factors, many of which are

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

outside of our control. For example, historically a significant portion of our laser system orders for a particular quarter have been received and shipped near the end of the quarter. As a result, our operating results for any quarter often depend on the timing of the receipt of orders and the subsequent shipment of our laser systems. Other factors that may cause our operating results or stock price to fluctuate include:

- o our significant liquidity and capital resource issues;
- o the addition or loss of significant customers;
- o reductions, cancellations or fulfillment of major orders;
- o changes in pricing by us or our competitors;
- o timing of regulatory approvals and the introduction or delays in shipment of new products;
- o the relative mix of our business; and
- o increased competition.

As a result of these fluctuations, we believe that period-to-period comparisons of our operating results cannot be relied upon as indicators of future performance. In some quarters our operating results may fall below the expectations of securities analysts and investors due to any of the factors described above or other uncertainties.

THE MARKET PRICE OF OUR COMMON STOCK MAY CONTINUE TO EXPERIENCE EXTREME FLUCTUATIONS DUE TO MARKET CONDITIONS THAT ARE UNRELATED TO OUR OPERATING PERFORMANCE.

The stock market, and in particular the securities of technology companies like us, could experience extreme price and volume fluctuations unrelated to our operating performance. Our stock price has historically been volatile. Because of the lengthy period during which our common stock traded below \$1 per share, it no longer met the listing requirements for the Nasdaq National Market and was transferred on August 9, 2002 to the Nasdaq SmallCap Market. On August 15, 2002, Nasdaq approved our application to transfer our listing to that market.

Factors such as announcements of technological innovations or new products by us or our competitors, changes in domestic or foreign governmental regulations or regulatory approval processes, developments or disputes relating to patent or proprietary rights, public concern as to the safety and efficacy of refractive vision correction procedures, and changes in reports and

29

recommendations of securities analysts, have and may continue to have a significant impact on the market price of our common stock.

THE SIGNIFICANT NUMBER OF SHARES ELIGIBLE FOR FUTURE SALE AND DILUTIVE STOCK ISSUANCES MAY ADVERSELY AFFECT OUR STOCK PRICE.

Sales, or the possibility of sales, of substantial amounts of our common stock in the public market could adversely affect the market price of our common stock. Substantially all of our 27,841,941 shares of common stock outstanding at November 13, 2002 were freely tradable without restriction or further registration under the Securities Act of 1933, except to the extent such shares are held by "affiliates" as that term is defined in Rule 144 under the Securities Act or subject only to the satisfaction of a prospectus delivery requirement. An additional 9,280,647 shares of preferred stock, convertible into 18,561,294 shares of common stock, were issued in October 2002 upon the funding of the equity investment portion of the China Transaction. We have agreed to register the shares of common stock under the Securities Act of 1933. Once registered, the shares will be available for sale.

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

Other shares of common stock that we may issue in the future in connection with financings or pursuant to outstanding warrants or agreements could also adversely affect the market price of our common stock and cause significant dilution in our earnings per share and net book value per share. We may be required to issue more than 5,800,000 additional shares of common stock upon the exercise of outstanding warrants and stock options. Including the China Transaction, the number of shares we may be required to issue upon the conversion of outstanding preferred stock and the exercise of outstanding warrants and stock options will increase to approximately 24,400,000.

The anti-dilution provisions of certain of our existing securities and obligations require us to issue additional shares if we issue shares of common stock below specified price levels. If a future share issuance triggers these adjustments, the beneficiaries of such provisions effectively receive some protection from declines in the market price of our common stock, while our other stockholders incur additional dilution of their ownership interest. We may include similar anti-dilution provisions in securities issued in connection with future financings.

THE CHINA TRANSACTION INCLUDES A PROVISION UNDER WHICH THE PURCHASER OF OUR PREFERRED STOCK CAN ACQUIRE APPROXIMATELY 40% OF OUR COMMON STOCK. THAT STOCKHOLDING POSITION ALONE DIMINISHES THE POSSIBILITY OF A COMPETING BID FOR A MAJORITY OF THE COMMON STOCK, BUT THE ANTI-TAKEOVER PROVISION UNDER DELAWARE LAW AND IN OUR CERTIFICATE OF INCORPORATION, OUR BY-LAWS AND OUR STOCKHOLDER RIGHTS PLAN WILL NONETHELESS REQUIRE THE BOARD TO EXERCISE ITS FIDUCIARY DUTY ON ANY BID (WHETHER BY THE PURCHASER IN THE CHINA TRANSACTION OR ANOTHER) TAKING INTO CONSIDERATION ALL OF THE CIRCUMSTANCES AT THAT TIME.

Certain provisions of our certificate of incorporation, by-laws, stockholder rights plan and Delaware law could delay or frustrate the removal of incumbent directors, discourage potential acquisition proposals and delay, defer or prevent a change in control of us, even if such events could be beneficial, in the short term, to the economic interests of our stockholders. For example, our certificate of incorporation allows us to issue preferred stock with rights senior to those of the common stock without stockholder action, and our by-laws require advance notice of director nominations or other proposals by stockholders. We also are subject to provisions of Delaware corporation law that prohibit a publicly-held Delaware corporation from engaging in a broad range of business combinations with a person who, together with affiliates and associates, owns 15% or more of the corporation's common stock (an interested stockholder) for three years after the person became an interested stockholder, unless the business combination is approved in a prescribed manner. We also have adopted a stockholder rights agreement, or "poison pill," and declared a dividend distribution of one preferred share purchase right for each share of common stock.

The board will act with respect to anti-takeover provisions with its fiduciary duty in mind.

30

RISKS RELATING TO INTANGIBLES

AMORTIZATION AND CHARGES RELATING TO OUR SIGNIFICANT INTANGIBLE ASSETS COULD ADVERSELY AFFECT OUR STOCK PRICE AND REPORTED NET INCOME OR LOSS.

Of our total assets at September 30, 2002, approximately \$4.9 million, or 20%, were intangible assets. Any reduction in net income or increase in net loss resulting from the amortization of intangible assets resulting from future acquisitions by us may have an adverse impact upon the market price of our common stock. In addition, in the event of a sale of LaserSight or our assets,

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

we cannot be certain that the value of such intangible assets would be recovered.

In accordance with FASB Statement No. 144, we review intangible assets for impairment whenever events or changes in circumstances, including a history of operating or cash flow losses, indicate that the carrying amount of an asset may not be recoverable. If we determine that an intangible asset is impaired, a non-cash impairment charge would be recognized.

OTHER RISKS

The following relates to risks on both a short and longer-term basis:

The risks described above are not the only risks facing LaserSight. There may be additional risks and uncertainties not presently known to us or that we have deemed immaterial which could also negatively impact our business operations. If any of the foregoing risks actually occur, it could have a material adverse effect on our business, financial condition and results of operations. In that event, the trading price of our common stock could decline, and you may lose all or part of your investment.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We believe that our exposure to market risk for changes in interest and currency rates is not significant. Our investments are limited to highly liquid instruments generally with maturities of three months or less. At September 30, 2002, we had approximately \$0.1 million of short-term investments classified as cash and equivalents. All of our transactions with international customers and suppliers are denominated in U.S. dollars.

ITEM 4. CONTROLS AND PROCEDURES

(a) Based on their evaluation within 90 days prior to the filing date of this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined in Rule 13a-14(c) under the Securities and Exchange Act of 1934, as amended, are effective for gathering, analyzing, and disclosing, the information we are required to disclose in our reports filed under the Act.

(b) There were no significant changes in our internal controls or in other factors that could significantly affect those controls since the date of evaluation of those internal controls.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Certain legal proceedings against LaserSight are described in Item 3 (Legal Proceedings) of LaserSight's Form 10-K for the year ended December 31, 2001. These matters are updated as follows:

Jarstad. In this matter, a settlement agreement has been signed by all parties. The terms of the settlement agreement do not require us to make any cash payments.

Distributors. We filed a motion for summary judgment that was denied. We then filed our answer and counterclaim. The plaintiffs have answered the counterclaim and have moved to strike some of our affirmative defenses and we have moved to strike portions of the

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

plaintiff's answer. To date, limited discovery has occurred. Management believes that LaserSight Technologies has satisfied its obligations under the distribution agreements, and that the allegations against LaserSight Technologies, Mr. Farris and Mr. Spivey are without merit and intend to vigorously defend this lawsuit. Management believes that the outcome of this litigation will not have a material adverse impact on LaserSight's business, financial condition or results from operations. However, the outcome of litigation is inherently uncertain, and an unfavorable outcome in this litigation could have a material adverse effect on LaserSight's business, financial condition and results from operations.

Former shareholder of TFG. We have agreed to the terms of a settlement with the plaintiff. During the three months ended September 30, 2002, we recorded settlement expense of approximately \$140,000 related to this settlement.

Lambda Physik, Inc. After no activity for over a year, the plaintiff filed a motion in July 2002 to have the court set a trial date, which they set for December 2002. Subsequently, the plaintiff filed a motion for continuance of the trial to allow the parties an opportunity to settle the dispute. In October 2002, the court entered an order continuing the trial and will reschedule only upon the filing of a new notice for trial by either party. We continue to believe that the allegations made by the plaintiff are without merit, and we intend to vigorously defend the action. Management believes that we have satisfied our obligations under the agreement and that this action will not have material adverse effect on our financial condition or results from operations.

Kremer. We have agreed to postpone discovery while we attempt to agree on the final form of a settlement with the plaintiffs. The terms of the settlement agreement, as currently contemplated, will not require us to make any cash payments.

ITEM 2. CHANGES IN SECURITIES

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

On August 15, 2002, Heller provided a temporary waiver of our prior defaults under our loan agreement. The waiver became permanent upon the funding of the equity investment portion of the China Transaction in October 2002.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable

ITEM 5. OTHER INFORMATION

Not applicable.

32

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

a) Exhibits

Exhibit

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

Number	Description
3.1	Certificate of Incorporation, as amended.
3.2	Bylaws, as amended.
3.3	Fourth Amendment to Rights Agreement, dated as of August 15, 2002, between LaserSight Incorporated and American Stock Transfer & Trust Company, as Rights Agent.
10.1	Amendment No. 2 to Loan and Security Agreement dated as of August 15, 2002 among LaserSight Incorporated and subsidiaries and Heller Healthcare Finance, Inc.
11	Statement of Computation of Loss Per Share
15	Copy of letter from independent accountants' regarding unaudited interim financial information
	b) Reports on Form 8-K
	<p>On August 14, 2002, we filed a Current Report on Form 8-K with Chief Executive Officer and Chief Financial Officer certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed under Item 9 to the Company's Form 8-K filed on August 14, 2002).</p> <p>On August 30, 2002, we filed a Current Report on Form 8-K describing our press release dated August 29, 2002 related to our record and annual meeting dates and containing material agreements related to our previously announced China transaction. The following exhibits were included:</p> <p>Securities Purchase Agreement dated August 15, 2002 between LaserSight Incorporated and New Industries Investment Consultants (H.K.) Ltd. The Company undertakes to provide to the Commission upon its request the schedules omitted from this exhibit (filed as Exhibit 99.2 to the Company's Form 8-K filed on August 30, 2002).</p> <p>Series H Registration Rights Agreement dated August 15, 2002 between LaserSight Incorporated and New Industries Investment Consultants (H.K.) Ltd. (filed as Exhibit 99.3 to the Company's Form 8-K filed on August 30, 2002).</p> <p>Product Purchase Agreement dated August 15, 2002 between LaserSight Technologies, Inc. and Shenzhen New Industries Medical Development Co., Ltd. The Company undertakes to provide to the Commission upon its request the schedules omitted from this exhibit (filed as Exhibit 99.4 to the Company's Form 8-K filed on August 30, 2002)*.</p> <p>Distribution Agreement dated August 15, 2002 LaserSight Technologies, Inc. and Shenzhen New Industries Medical Development Co., Ltd. (filed as Exhibit 99.5 to the Company's Form 8-K filed on August 30, 2002)*.</p>

* Confidential treatment has been requested for portions of this document. The redacted material has been filed separately with the commission.

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the undersigned have duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LaserSight Incorporated

Dated: November 14, 2002

By: /s/ Michael R. Farris

Michael R. Farris
Chief Executive Officer

Dated: November 14, 2002

By: /s/ Gregory L. Wilson

Gregory L. Wilson
Chief Financial Officer

CERTIFICATIONS PURSUANT TO RULE 13A-14 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Michael R. Farris, Chief Executive Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of LaserSight Incorporated;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared.
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

Evaluation Date;

34

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

/s/ Michael R. Farris

Principal Executive Officer
November 14, 2002

I, Gregory L. Wilson, Chief Financial Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of LaserSight Incorporated;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

35

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

- a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared.
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
- a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

/s/ Gregory L. Wilson

Principal Financial Officer
November 14, 2002

INDEX TO EXHIBITS

Exhibit Number	Description
3.1	Certificate of Incorporation, as amended.
3.2	Bylaws, as amended.
3.3	Fourth Amendment to Rights Agreement, dated as of August 15, 2002, between LaserSight Incorporated and American Stock Transfer & Trust

Edgar Filing: LASERSIGHT INC /DE - Form 10-Q

Company, as Rights Agent.

- 10.1 Amendment No. 2 to Loan and Security Agreement dated as of August 15, 2002 among LaserSight Incorporated and subsidiaries and Heller Healthcare Finance, Inc.
- 11 Statement of Computation of Loss Per Share
- 15 Copy of letter from independent accountants' regarding unaudited interim financial information